Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tissue samples from patients with acute myeloid leukemia.
Genetic: cytogenetic analysis
Other: HUMARA assay
Other: fluorescence activated cell sorting
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Assessment of Stem Cell Heterogeneity in AML in Co-Culture Systems Using X Chromosome Inactivation Patterns|
- Frequency of AML that originate in CD33+ or in which uncontrolled growth is restricted to CD33+ precursors [ Designated as safety issue: No ]
- Extent of clonal hematopoiesis in small numbers of AML cells [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||October 2010|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- Determine the frequency of acute myeloid leukemia (AML) that originates in CD33+ precursors or in which uncontrolled growth is restricted to CD33+ precursors.
OUTLINE: Cryopreserved acute myeloid leukemia cell samples are separated from endothelial cell by fluorescent-activated cell sorting (FACS) and analyzed for X-chromosome inactivation patterns by cytogenetic/molecular analysis and/or Humara assay.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01232842
|Principal Investigator:||Roland Walter, MD, PhD||Fred Hutchinson Cancer Research Center|